Related Experiment Video
Updated: Apr 16, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Searching for targets for the systemic therapy of mesothelioma
R A Stahel1, W Weder2, E Felley-Bosco3
1Department of Oncology, University Hospital, Zürich rolf.stahel@usz.ch.
Abstract:
Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less frequently in the peritoneal cavity. Platinum-based combination chemotherapy with pemetrexed is the established standard of care. Multimodality approaches including surgery and radiotherapy are being investigated. Increasing knowledge about the molecular characteristics of mesothelioma had led to the identification of novel potential targets for systemic therapy. Current evidence suggests pathways activated in response to merlin deficiency, including Pi3K/mTOR and the focal adhesion kinase, as well as immunotherapeutic approaches to be most promising. This review elaborates on the rationale behind targeted approaches that have been and are undergoing exploration in mesothelioma and summarizes available clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.
Insights
Malignant mesothelioma, an incurable cancer linked to asbestos, is exploring new treatments beyond standard chemotherapy. Promising avenues include targeted therapies and immunotherapies based on molecular insights.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Malignant mesothelioma is an incurable cancer primarily linked to asbestos exposure.
- Current standard care involves platinum-based chemotherapy with pemetrexed.
- Multimodality treatments and novel molecular targets are under investigation.
Purpose of the Study:
- To review the rationale and clinical results of targeted therapies for malignant mesothelioma.
- To summarize ongoing efforts in improving systemic therapy for this disease.
- To highlight promising molecular pathways and immunotherapeutic approaches.
Main Methods:
- Literature review of preclinical and clinical studies on mesothelioma targeted therapies.
- Analysis of molecular pathways implicated in mesothelioma pathogenesis, such as merlin deficiency-related signaling.
- Summary of clinical trial data for novel systemic treatments.
Main Results:
- Targeted therapies focusing on pathways like Pi3K/mTOR and focal adhesion kinase show promise.
- Immunotherapeutic approaches are emerging as a significant area of research.
- Understanding mesothelioma's molecular landscape is crucial for developing effective treatments.
Conclusions:
- Targeted therapies and immunotherapies represent the future of malignant mesothelioma treatment.
- Further research is needed to optimize these novel approaches and improve patient outcomes.
- Personalized medicine based on molecular characteristics holds potential for mesothelioma management.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies